TITLE

Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans

AUTHOR(S)
smith, john; johnson, joe
PUB. DATE
August 2010
SOURCE
TEST DATA_New England Patriots EDSYS;08032010, p41
SOURCE TYPE
Book
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
52583355

 

Related Articles

  • Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes. Heise, Tim; Nosek, Leszek; Rønn, Birgitte Biilmann; Endahl, Lars; Heinemann, Lutz; Kapitza, Christoph; Draeger, Eberhard // Diabetes;Jun2004, Vol. 53 Issue 6, p1614 

    The aim of this randomized double-blind study was to compare the within-subject variability of the glucoselowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age 38...

  • Insulin Glargine. Gillies, P.S.; Figgitt, D.P.; Lamb, H.M. // Drugs;Feb2000, Vol. 59 Issue 2, p253 

    â–´ Insulin glargine is an extended-action biosynthetic human insulin. It precipitates in the neutral environment of subcutaneous tissue and is thus gradually absorbed into the bloodstream. The addition of small amounts of zinc to the formulation further delays absorption. â–´ In small...

  • Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus. PORCELLATI, FRANCESCA; LUCIDI, PAOLA; ROSSETTI, PAOLO; CANDELORO, PAOLA; ANDREOLI, ANNA MARINELLI; MARZOTTI, STEFANIA; CIOLI, PATRIZIA; BOLLI, GEREMIA B.; FANELLI, CARMINE G. // Diabetes Care;Dec2011, Vol. 34 Issue 12, p2521 

    OBJECTIVE--To assess the role of adiposity on the pharmacodynamics of basal insulins NPH, detemir, and glargine in type 2 diabetes mellitus (T2DM), as estimated by glucose infusion rate (GIR) and endogenous glucose production (EGP) rate in the euglycemic clamp. RESEARCH DESIGN AND METHODS--We...

  • Insulin Detemir and Its Unique Mechanism of Action. Chaykin, Louis B. // Internet Journal of Endocrinology;2007, Vol. 4 Issue 1, p1 

    Tight glycemic control with minimal risk for hypoglycemia is the goal of insulin therapy. Such control is difficult to accomplish with older insulin formulations, such as regular human insulin and neutral protamine Hagedorn (NPH) insulin because their pharmacokinetic/pharmacodynamic profiles...

  • Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects. LUCIDI, PAOLA; PORCELLATI, FRANCESCA; ROSSETTI, PAOLO; CANDELORO, PAOLA; CIOLI, PATRIZIA; MARZOTTI, STEFANIA; ANDREOLI, ANNA MARINELLI; FEDE, RAFFAELA; BOLLI, GEREMIA B.; FANELLI, CARMINE G. // Diabetes Care;Jun2011, Vol. 34 Issue 6, p1312 

    OBJECTIVE--To compare the pharmacokinetics and pharmacodynamics of NPH, glargine, and detemir insulins in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS--This study used a single-blind, three-way, cross-over design. A total of 18 type 2 diabetic subjects underwent a euglycemic clamp for...

  • Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Scholtz, H. E.; Pretorius, S. G.; Wessels, D. H.; Becker, R. H. A. // Diabetologia;Oct2005, Vol. 48 Issue 10, p1988 

    Aims/hypothesis: This single-dose, double-blind, randomised, parallel-group study evaluated the reproducibility in systemic exposure and glucodynamic effect of insulin glargine, NPH insulin (N PH) and insulin ultralente (ultralente) using the manually adjusted euglycaemic clamp technique....

  • Insulin Detemir: A Review of its Use in the Management of Diabetes Mellitus. Keating, Gillian M.; Evans, M.; Kabadi, U. M.; Karnieli, E.; Mooradian, A. D.; Rašlová, K.; Ross, S. A. // Drugs;2012, Vol. 72 Issue 17, p2255 

    Insulin detemir (Levemir®) is a long-acting insulin analogue indicated for use as basal insulin therapy in patients with type 1 or 2 diabetes mellitus. The protracted action of insulin detemir is explained by increased self-association and reversible binding to albumin, which slows its...

  • Spotlight on Insulin Detemir in Type 1 and 2 Diabetes Mellitus. Chapman, Therese M.; Perry, Caroline M. // BioDrugs;2005, Vol. 19 Issue 1, p67 

    Insulin detemir (Levemir®) is a soluble long-acting human insulin analog acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours...

  • Insulin Detemir: A Review of its Use in the Management of Type 1 and 2 Diabetes Mellitus. Chapman, Therese M.; Perry, Caroline M. // Drugs;2004, Vol. 64 Issue 22, p2577 

    Insulin detemir (Levemir®) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24...

  • New Insulin Analogues and Routes of Delivery. Roach, Paris // Clinical Pharmacokinetics;2008, Vol. 47 Issue 9, p595 

    Analogues of human insulin have been developed to more closely replicate the physiology of meal-related and basal insulin secretion. Three rapid-acting analogues and two basal analogues are available for clinical use. Insulin aspart and insulin lispro have nearly identical pharmacokinetic and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics